A Phase II Study of Dasatinib (NSC 732517) in Patients With Previously Treated Malignant Mesothelioma.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Dasatinib (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 11 Aug 2016 Biomarkers information updated
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 21 Jun 2011 Planned end date changed from 1 Jul 2008 to 1 Aug 2013 as reported by ClinicalTrials.gov.